pharma · Generalized Pustular Psoriasis · Schizophrenia · VNDA
Vanda Pharmaceuticals Netherlands
Vanda Pharmaceuticals Netherlands B.V.
Vanda Pharmaceuticals Netherlands is a pharma organization headquartered in Washington, USA. It trades on NYSE under ticker VNDA. Primary therapeutic focus areas include Generalized Pustular Psoriasis, Schizophrenia, Maj
2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US HQ
2003 Founded
600 Employees
Public company Type
VNDA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US
- Founded
- 2003
- Employees
- 600
- Programs
- 60
- Drugs
- 19
- Patents
- 96
tasimelteon 20 mg capsule
Approved · small molecule · Non-24-Hour-Sleep-Wake Disorder
tasimelteon 20 mg capsule for Non-24-Hour-Sleep-Wake Disorder is a Approved program (small_molecule) at Vanda Pharmaceuticals Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code VP-VEC-162-4101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Vanda Pharmaceuticals Netherlands B.V.
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Non-24-Hour-Sleep-Wake Disorder
- Status
- completed
- Trials
- 1